Relationship of ADP-Induced Fibrinogen Binding to Platelet Shape Change and Aggregation Elucidated by Use of Colchicine and Cytochalasin B

Summary

ADP causes human, aspirin-treated, gel-filtered platelets to change from their native discoid shape to spiny spheres with pseudopods, bind ¹²⁵I-labeled fibrinogen, and aggregate if shaken with sufficient fibrinogen. After destruction of the added ADP with the enzyme apyrase, the platelets revert to a disc shape and lose much of their bound fibrinogen. Colchicine (208 μM or 83 μg/ml) added to ADP-treated platelets before apyrase prevented restoration of the discoid shape but not the loss of bound fibrinogen. It did not inhibit ADP-induced shape change, aggregation, or fibrinogen binding. Cytochalasin B (0.02–0.2 μM or 0.01–0.10 μg/ml) prevented ADP-induced shape change but not ADP-induced fibrinogen binding or aggregation. Thus, these findings support earlier studies with thrombasthenic and EDTA-treated platelets and with normal platelets at low pH, or in the presence of EDTA to indicate that fibrinogen binding is associated with aggregability but not with platelet shape.

Keywords

Platelet aggregation - Fibrinogen binding (to platelets) - Colchicine - Cytochalasin B - ADP

• References

• 1 Zucker MB, Zaccardi JB. Platelet shape change induced by adenosine diphosphate and prevented by adenosine monophosphate. Fed Proc 1964; 23: 299
• 2 O'Brien JF, Heywood JB. Effect of aggregating agents and their inhibitors on the mean platelet shape. J Clin Path 1966; 19: 148-153
• 3 Mustard JF, Packham MA, Kinlough-Rathbone RL, Perry DW, Regoeczi E. Fibrinogen and ADP-induced aggregation. Blood 1978; 52: 453-466
• 4 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-5363
• 5 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-1401
• 6 Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood, May 1980
• 7 Phillips DR, Agin PP. Platelet membrane defects in Glanzmann’s thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977; 60: 535-545
• 8 White JG. Effect of colchicine and vinca alkaloids on human platelets. III. Influence on primary internal contraction and secondary aggregation. Am J Pathol 1969; 54: 467-478
• 9 White JG. Platelet microtubules and microfilaments. Effects of cytochalasin B on structure and function. In: Aggregation Platelet, Caen J. (Ed.) Masson, Paris: 1971. p. 15-52
• 10 Packham MA, Mustard JF. Clinical pharmacology of platelets. Blood 1977; 50: 555-573
• 11 Walsh PN. Albumin density gradient separation and washing of platelets and study of platelet coagulant activities. Br J Haematol 1972; 22: 205-217
• 12 Tangen O, Berman HJ, Marfey P. Gel filtration. A new technique for separation of blood platelets from plasma. Thromb Diath Haemorrh 1971; 25: 268-278
• 13 White JG. Fine structural changes induced in platelets by adenosine diphosphate. Blood 1968; 31: 604-622
• 14 Plow EF, Marguerie G, Edgington TS. Induction of the fibrinogen receptor on human platelets by epinephrine. Blood 1979; 54: 257